Treatment landscape and prognosis after treatment with trastuzumab emtansine

Publikation: Beitrag in FachzeitschriftForschungsartikelBeigetragenBegutachtung

Beitragende

  • Elena Laakmann - , Universität Hamburg (Autor:in)
  • Julius Emons - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Florin Andrei Taran - , Universität Zürich (Autor:in)
  • Wolfgang Janni - , Universität Ulm (Autor:in)
  • Sabrina Uhrig - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Friedrich Overkamp - , Oncologianova GmbH (Autor:in)
  • Hans Christian Kolberg - , Marienhospital Bottrop (Autor:in)
  • Peyman Hadji - , Frankfurt Center of Bone Health (Autor:in)
  • Hans Tesch - , Agaplesion Markus Krankenhaus Frankfurt (Autor:in)
  • Lothar Häberle - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Johannes Ettl - , Technische Universität München (Autor:in)
  • Diana Lüftner - , Charité – Universitätsmedizin Berlin (Autor:in)
  • Markus Wallwiener - , Universität Heidelberg (Autor:in)
  • Carla Schulmeyer - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Volkmar Müller - , Universität Hamburg (Autor:in)
  • Matthias W. Beckmann - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Erik Belleville - , Clin-Sol GmbH (Autor:in)
  • Pauline Wimberger - , Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe (Autor:in)
  • Carsten Hielscher - , G.SUND Center for Gynecologic Oncology Stralsund (Autor:in)
  • Christian Kurbacher - , Gynäkologischen Zentrums Bonn-Friedensplatz (Autor:in)
  • Rachel Wuerstlein - , Ludwig-Maximilians-Universität München (LMU) (Autor:in)
  • Christoph Thomssen - , Martin-Luther-Universität Halle-Wittenberg (Autor:in)
  • Michael Untch - , HELIOS Klinikum Berlin-Buch (Autor:in)
  • Bernhard Volz - , Hochschule für angewandte Wissenschaften Ansbach (Autor:in)
  • Peter A. Fasching - , Friedrich-Alexander-Universität Erlangen-Nürnberg (Autor:in)
  • Tanja N. Fehm - , Universitätsklinikum Düsseldorf (Autor:in)
  • Diethelm Wallwiener - , Eberhard Karls Universität Tübingen (Autor:in)
  • Sara Y. Brucker - , Eberhard Karls Universität Tübingen (Autor:in)
  • Andreas Schneeweiss - , Universität Heidelberg (Autor:in)
  • Andreas D. Hartkopf - , Eberhard Karls Universität Tübingen (Autor:in)

Abstract

Purpose Pertuzumab and T-DM1 are two efficient anti-HER2 treatments for patients with HER2-positive advanced breast cancer. While pertuzumab is usually given in first-line treatment and T-DM1 in second-line treatment, standard therapy options seem to be exhausted up to now after the treatment of patients with these two therapy options. Therefore, it is important to have data that describes the therapy situation and prognosis after T-DM1 treatment. Methods The PRAEGNANT metastatic breast cancer registry (NCT02338167) is a prospective registry for breast cancer patients with a focus on molecular biomarkers. Patients of all therapy lines with any kind of treatment are eligible. Collected data comprises therapies, adverse events, quality of life and other patient reported outcomes. Here we report on the patient characteristics and descriptive prognostic data for HER2-positive patients who have completed a treatment with T-DM1. Therapy patterns after T-DM1 and progression-free survival are reported as well as overall survival. Results A total of 85 patients were identified for the study who were prospectively observed during therapy after the termination of T-DM1. The main reason for T-DM1 termination was progress. Following T-DM1, lapatinib, trastuzumab and chemotherapy were the main therapy choices. Median progression-free survival was 4.8 months (95% CI: 3.2-6.3) and median overall survival was 18.4 months (95% CI: 15.5-21.3). Conclusions Therapy options after T-DM1 in a real-world setting seem to exhibit a relevant clinical efficacy, supporting the concept of continuous anti-HER2 treatments in the advanced therapy setting for breast cancer patients. Novel therapies are needed to improve the rather short median progression-free survival.

Details

OriginalspracheEnglisch
Seiten (von - bis)1134-1142
Seitenumfang9
FachzeitschriftGeburtshilfe und Frauenheilkunde
Jahrgang80
Ausgabenummer11
PublikationsstatusVeröffentlicht - 1 Nov. 2020
Peer-Review-StatusJa

Schlagworte

Ziele für nachhaltige Entwicklung

Schlagwörter

  • advanced breast cancer, antihormone therapy, chemotherapy, HER2 c-erbB2, HER2/neu, lapatinib, metastatic, pertuzumab, T-DM1, trastuzumab